title: Induction of severe systemic lupus erythematosus by TNF blockade and response to anti-IL-6 strategy.
authors.forename: Sabine
authors.initials: S
authors.lastname: Adler
authors.forename: Mirjam
authors.initials: M
authors.lastname: Kolev
authors.forename: Pierre-Alain
authors.initials: PA
authors.lastname: Varisco
authors.forename: Manuela
authors.initials: M
authors.lastname: Tham
authors.forename: Michael
authors.initials: M
authors.lastname: von Gunten
authors.forename: Christoph
authors.initials: C
authors.lastname: Tappeiner
authors.forename: Peter M
authors.initials: PM
authors.lastname: Villiger
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000974:Antibodies, Antinuclear / Q000097:blood / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D004696:Endocarditis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000473:pathology; D000069285:Infliximab; D015850:Interleukin-6 / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D008297:Male; D015423:Scleritis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology; D000093242:Interleukin-6 Inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069285:Infliximab; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors; C502936:tocilizumab